ACP
TERN

Acuta Capital Partners’s Terns Pharmaceuticals TERN Stock Holding History

Acuta Capital Partners’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.1M Sell
495,772
-141,323
-22% -$5.8M 18.44% 2
2025
Q4 		$25.7M Buy
637,095
+134,298
+27% +$3.1M 17.48% 1
2025
Q3 		$3.78M Buy
502,797
+38,933
+8% +$249K 3.9% 9
2025
Q2 		$1.73M Buy
463,864
+138,314
+42% +$432K 2.42% 15
2025
Q1 		$899K Sell
325,550
-121,950
-27% -$498K 1.04% 25
2024
Q4 		$2.48M Sell
447,500
-39,500
-8% -$267K 2.49% 15
2024
Q3 		$4.06M Buy
487,000
+117,720
+32% +$969K 3.29% 11
2024
Q2 		$2.51M Sell
369,280
-95,799
-21% -$580K 2.12% 19
2024
Q1 		$3.05M Sell
465,079
-90,181
-16% -$589K 1.98% 19
2023
Q4 		$3.6M Hold
555,260
– – 2.03% 21
2023
Q3 		$2.79M Sell
555,260
-414,740
-43% -$2.63M 1.87% 20
2023
Q2 		$8.49M Sell
970,000
-129,309
-12% -$1.51M 5.75% 3
2023
Q1 		$13M Sell
1,099,309
-691
-0.1% -$6.6K 9.59% 3
2022
Q4 		$11.2M Buy
1,100,000
+749,298
+214% +$4.99M 6.89% 4
2022
Q3 		$2.07M Buy
+350,702
New +$1.3M 0.89% 26

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Acuta Capital Partners's TERN Position: Q1 2026 in Review

Acuta Capital Partners reduced its Terns Pharmaceuticals (TERN) stake by 22% in Q1 2026, selling an estimated $5.8M and leaving 495,772 shares worth $26.1M. The position accounts for 18.44% of the portfolio, ranked #2.

Acuta Capital Partners first reported a position in TERN in Q3 2022 and has held it in 15 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Acuta Capital Partners held 495,772 shares of Terns Pharmaceuticals worth $26.1M as of Q1 2026.
  • Acuta Capital Partners sold 141,323 Terns Pharmaceuticals shares in Q1 2026, an estimated $5.8M.
  • Terns Pharmaceuticals made up 18.44% of Acuta Capital Partners's portfolio in Q1 2026, its #2 holding.
  • Acuta Capital Partners first reported a position in Terns Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.